Sovaldi, the $1,000 pill
The eye-popping price tag on the hepatitis C drug, from Gilead Sciences, has prompted unprecedented pushback from payers
Bending the cost curve in oncology
A rising flow of new, expensive therapies is transforming relationships among payers and providers. Manufacturers will have to react nimbly to the changes
Copay programs' increased value to manufacturers is matched by rising criticism
Despite proven medical value, coupon and copay offset programs continue to draw fire from insurers; meanwhile, will the programs extend to ACA insureds?
Biomarkers and companion diagnostics expand drug potential
Essential for approving some new products, biomarkers are becoming integrated with patient therapies
Industry confronts healthcare's changing oncology practices
Health systems and community oncologists are fighting over a preferred position as care providers, while payers tighten purse strings
Pharma struggles to manage the complexity of its Patient Assistance Programs
While awaiting the effects of the Affordable Care Act on PAPs, industry and its service providers wrestle with conflicting priorities
Psychoactive Drugs: Getting the Whole Support Team on Board
More so than other classes of drugs, making choices about drugs for mental health conditions require everyone around the patient to be well informed